Figure 2.

LPA₁ antagonism prevents serum-induced schizophrenia-like behavioral deficits in females. (a) LPA₁ antagonism through Ki16425 treatment did not prevent prenatal serum-induced decreases in locomotor activity, but did prevent AMPH-induced hyperlocomotion. (b and c) Treatment with Ki16425 prevented prenatal serum-induced deficits in PPI at 100 dB. (d–e) Ki16425 treatment also prevented the decreased percentage of time female serum-exposed mice spent in the center of the open-field box over a 30-min period (d), but had no effect on serum-induced social interaction deficits (e). Data for vehicle and serum are as in Figure 1. All data were analyzed with multivariate two-way analysis of variance comparisons between groups (vehicle, serum, LPA and Ki16425+serum). n=6–17 per group, mean±s.e.m., ^*P<0.05, ^***P<0.001. LPA, lysophosphatidic acid; NS, not significant; PPI, prepulse inhibition.